^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

Association between soluble PD-L1 and prognosis of non-small cell lung cancer (NSCLC) patients treated with immunotherapy

Published date:
09/14/2020
Excerpt:
In Pembro cohort, median overall survival in low and high sPD-L1 level groups were 16.0 and 10.9 months, respectively (p=0.045). No difference in progression-free survival or objective response was observed...baseline sPD-L1 is associated with poor prognosis in advanced NSCLC patients treated with Pembro in first line.